Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + ginsenoside
- Development stage
- Unknown
- Lead developer
- Hangzhou Jinshennuo Biopharmaceutical
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Doxorubicin + ginsenoside is a liposomal formulation of the anthracycline chemotherapy agent doxorubicin, utilizing ginsenosides (specifically ginsenoside Rg3) as a functional membrane material. Developed by Xiamen Ginposome Pharmaceutical using their proprietary Ginposome drug delivery system (DDS), this formulation aims to enhance the delivery and therapeutic profile of doxorubicin. Doxorubicin acts by intercalating DNA and inhibiting topoisomerase II, leading to cell death in rapidly dividing cancer cells. The inclusion of ginsenosides in the liposomal bilayer is intended to improve stability and potentially provide synergistic anti-tumor or cardioprotective effects. While other Ginposome products (such as GF07 and GF11) are in late-stage development, the doxorubicin formulation is currently listed in patent materials with no disclosed clinical phase.
- Other names
- doxorubicin ginsenoside liposomeginsenoside-based liposomal doxorubicin
02
Targets
DNAGLUT1 (Glucose transporter 1)TOP2B (DNA topoisomerase II beta)AHR (Aryl hydrocarbon receptor)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin + ginsenoside.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + ginsenoside.